Wells Fargo Reaffirms Buy Rating on NeuroPace with $15 Price Target

Vik Chopra from Wells Fargo maintains a Buy rating for NeuroPace with a price target of $15.00. The analyst consensus is a Strong Buy with an average price target of $16.14, representing a 76.78% upside. Chopra has an average return of -3.9% and a 30.26% success rate.

Neuropace Inc (NPCE) has seen its stock price fluctuate in recent weeks, with analysts maintaining a strong buy rating despite the volatility. Vik Chopra from Wells Fargo has issued a buy rating for NeuroPace with a price target of $15.00, while the consensus among analysts is a strong buy with an average price target of $16.14, representing a 76.78% upside [1].

The recent price movement for NeuroPace has been significant, with the stock reaching a 52-week high of $17.88 in May 2025. However, the stock has since experienced a decline, reflecting market sentiment following clinical study results. On May 19, 2025, shares of NeuroPace Inc plummeted 36.1% after the company reported mixed results in an epilepsy study [2].

Despite the recent decline, analysts remain optimistic about NeuroPace's growth potential. The company's revenue growth has been robust, with a 16-21% year-over-year increase projected for FY25. Additionally, NeuroPace targets a $1.4 billion addressable market, with potential to double through expanded indications in epilepsy treatment [3].

Chopra's average return of -3.9% and a 30.26% success rate indicate a relatively cautious approach, with a focus on long-term growth rather than short-term gains. This aligns with the company's strategic initiatives, including AI integration and hardware upgrades, which aim to enhance its competitive edge in the medical device industry [4].

In conclusion, while recent volatility has impacted NeuroPace's stock price, analysts maintain a strong buy rating, reflecting optimism about the company's growth potential. Investors should closely monitor the company's clinical trial results and financial performance to make informed investment decisions.

References:

[1] Investing.com. (2025, July 02). NeuroPace Inc: Analysts Maintain Strong Buy Rating Despite Recent Volatility. Retrieved from https://www.investing.com/equities/neuropace

[2] Investing.com. (2025, May 19). NeuroPace stock sinks following clinical study results. Retrieved from https://www.investing.com/equities/neuropace

[3] Investing.com. (2025, May 13). NeuroPace Reports First Quarter 2025 Financial Results. Retrieved from https://www.investing.com/equities/neuropace

[4] Investing.com. (2025, May 14). NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study. Retrieved from https://www.investing.com/equities/neuropace